Save up -80% on Ceritinib

Note: this is a drug discount program, not an insurance plan.

RX BIN: 015558
RX PCN: HT
Group ID: DDN6600
Card Holder ID: DDN6600

Pharmacists and Patients support.

2018 Price of Zykadia

$3,304

150mg

* price without discount in nearest pharmacy. Price may vary.

Claim your free Ceritinib discount card

We offer free Ceritinib coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Ceritinib every time. What are you waiting for? Claim your prescription drug card now!

Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time

Ceritinib volume of distribution

The apparent volume of distribution (Vd/F) is 4230 L following a single 750 mg dose.

About RX24Drugs

Discount Cards 16,000+

Clients Benefit 29%

Total savings $4,735,080

What is Ceritinib

Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key “gatekeeper” residues of the enzyme. This occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance. The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.

Ceritinib mechanism of action

Ceritinib inhibits Anaplastic lymphoma kinase (ALK) also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246), which is an enzyme that in humans is encoded by the ALK gene. About 4-5% of NSCLCs have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Ceritinib has been shown to inhibit in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice and rats.

Dosage forms of Ceritinib

DrugDosageQuantityPrice
Zykadia150mg30 capsules$3,394
Zykadia150mg140 capsules$15,387
Prescription Generics

false

International Brands

Zykadia

Synonyms

ceritinib N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide

Manufacturers

Novartis Pharmaceuticals Corporation

CAS number

1032900-25-6

UNII

K418KG2GET

State

solid

Affected organisms

Indication of Ceritinib

Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Toxicity of Ceritinib

There is not currently any data on carcinogenicity, effect on human fertility, or on early embryonic development. However, based on its mechanism of action, ceritinib may cause fetal harm when administered to pregnant women and should therefore be administered with effective contraception during treatment. Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients. Drug-induced hepatotoxicity also occurred in 27% of 255 patients, presenting as alanine aminotransferase (ALT) levels greater than 5 times the upper limit of normal (ULN). Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis, hyperglycaemia, and bradycardia have also been reported.

RX24 Drugs Disclaimer: before buying a Ceritinib on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Ceritinib now!